Document is current

Any future updates will be listed below

Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits

Crossref DOI link: https://doi.org/10.1038/s41416-023-02159-4

Published Online: 2023-01-30

Published Print: 2023-02-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark